Ovid Therapeutics (OVID) has a bullish outlook due to its promising drug candidate OV329, which analysts believe could achieve over $600M in sales with just 5% market penetration. Oppenheimer recently upgraded the stock to "Outperform" with a price target of $4, while BTIG maintains a $5 target, reflecting confidence in its pipeline and financial stability. With the current price at $0.6965, this represents significant upside potential.